Amgen organizacji Net debt/EBITDA
Jaka jest wartość Net debt/EBITDA organizacji Amgen?
Wartość Net debt/EBITDA organizacji Amgen, Inc. to 0.13
Jaka jest definicja Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA firm w Health Care sektor na XETRA w porównaniu do Amgen
Czym się zajmuję organizacja Amgen?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Firmy z net debt/ebitda podobne do Amgen
- Wartość Net debt/EBITDA organizacji Sprott to 0.12
- Wartość Net debt/EBITDA organizacji Loop Insights to 0.12
- Wartość Net debt/EBITDA organizacji Loop Insights to 0.12
- Wartość Net debt/EBITDA organizacji Barings Participation Investors to 0.13
- Wartość Net debt/EBITDA organizacji BHP to 0.13
- Wartość Net debt/EBITDA organizacji Coherent Corp to 0.13
- Wartość Net debt/EBITDA organizacji Amgen to 0.13
- Wartość Net debt/EBITDA organizacji First Busey to 0.13
- Wartość Net debt/EBITDA organizacji BHP to 0.13
- Wartość Net debt/EBITDA organizacji BHP to 0.13
- Wartość Net debt/EBITDA organizacji Hopefluent to 0.13
- Wartość Net debt/EBITDA organizacji NewRange Gold to 0.13
- Wartość Net debt/EBITDA organizacji Dr.Ing.H.C.F.Porsche Vzoi to 0.13